Clinical summary of initial intravenous administration of ioversol.
Data from 23 double blind, controlled, parallel-group comparative studies evaluating the intravenous safety, efficacy, and patient tolerance of ioversol were collected. Nine open-label studies were evaluated, as well. A small number of side effects that would be considered serious were reported, but resulted in no clinically significant sequelae, (e.g., angina, bradycardia, vasovagal response, and hypoxia). There were no significant changes in vital signs related to the use of the drug. These studies indicate that ioversol 320 and 240 provide high diagnostic quality and are well tolerated by patients. The author concludes that ioversol is suitable for head and body computed tomography, intravenous urography, and venography.
McClennan
B L
BL
Abdominal Imaging Section, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri 63110.
D000328:Adult; D000368:Aged; D001831:Body Temperature / Q000187:drug effects; D002986:Clinical Trials as Topic; D003287:Contrast Media; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007463:Iodobenzoates / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D012107:Research Design; D014057:Tomography, X-Ray Computed; D014283:Triiodobenzoic Acids / Q000008:administration & dosage* / Q000633:toxicity
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; C054871:ioversol